Vista Pharmaceuticals Share Price
6.28+0.04 (+0.64%)
-38.19% past 1 Year
Vista Pharmaceuticals Limited is engaged in manufacturing and selling of Pharmaceutical, medical and veterinary preparations. It offers over the counter & prescription generic drug products consisting of tablets, capsules and
Corporate filings & documents
Announcements
Results for the quarter ended 30.06.2026
3 weeks agoResults for the quarter ended 30.06.2026
3 weeks agoResults for the quarter ended 30.06.2026
3 weeks agoResults for the quarter ended 30.06.2026
3 weeks agoVista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve 1. Unaudited financial results for the quarter ended 30.06.20262. Limited Review Report for the quarter ended 30.06.20263. Any other business with the permission of the Chair.
3 weeks agoVista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve 1. Unaudited financial results for the quarter ended 30.06.20262. Limited Review Report for the quarter ended 30.06.20263. Any other business with the permission of the Chair.
3 weeks agoCompliance - Certificate under Reg 74(5) of SEBI (DP)regulations 2018
1 month agoCompliance - Certificate under Reg 74(5) of SEBI (DP)regulations 2018
1 month agoClosure of Trading window
2 months agoClosure of Trading window
2 months agoSEBI Secretarial Compliance Report for the year ended 31.03.2026
3 months agoBoard meeting outcome
3 months agoBoard meeting outcome
3 months agoVista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve 1. Audited financial results for the quarter and year ended 31.03.20262. Audit Report for the quarter and year ended 31.03.20263. Any other business with the permission of the Chair.
3 months agoVista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2026 inter alia to consider and approve 1. Audited financial results for the quarter and year ended 31.03.20262. Audit Report for the quarter and year ended 31.03.20263. Any other business with the permission of the Chair.
3 months ago<b>Format of the Annual Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=1px> <tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> </tr> <tr> <td>1</td> <td>Name of Company</td> <td>Vista Pharmaceuticals Ltd</td> </tr> <tr> <td>2</td> <td>CIN NO.</td> <td>L24239TG1991PLC012264</td> </tr> <tr> <td>3</td> <td>Report filed for FY</td> <td>2025-2026</td> </tr> <tr><td colspan=3>Details of the Current block (all figures in Rs crore):</td><tr> <tr> <td>4</td> <td>2 - year block period (Specify financial years)* </td> <td>2025-26 2026-27</td> </tr> <tr> <tr> <td>5</td> <td>Incremental borrowing done in FY (T)(a) </td> <td>0.00</td> </tr> <tr> <td>6</td> <td>Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a)</td> <td>0.00</td> </tr> <tr> <td>7</td> <td>Actual borrowing done through debt securities in FY (T)(c)</td> <td>0.00</td> </tr> <tr> <td>8</td> <td> Shortfall in the borrowing through debt securities if any for FY (T - 1) carried forward to FY (T) (d)</td> <td>0</td> </tr> <tr> <td>8</td><td>Quantum of (d) which has been met from (c)(e)*</td> <td>0</td> </tr><tr> <td>9</td><td> Shortfall if any in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative write nil}*</td> <td>0</td> </tr> </table> <br/><br/><table><tr><td colspan=2><b>Details of penalty to be paid if any in respect to previous block (all figures in Rs crore):</b></td></tr> <tr><td>2 - year Block period (Specify financial years)</td><td>2024-25 2025-26</td></tr> <tr><td>Amount of fine to be paid for the block if applicable Fine = 0.2% of {(d) - (e)}#</td><td>0.00</td></tr> </table> <div> <br/><br/><br/> <table><tr><td>Name of the Company Secretary :-</td><td>Barka Jain</td></tr><tr><td>Designation :-</td><td>Company Secretary compliance Officer</td></tr> <tr><td>Name of the Chief Financial Officer :- </td><td>Suneel pachipala</td></tr> <tr><td>Designation : -</td><td>CFO</td></tr></table><div> <br/> Date: 29/04/2026<br/><br/></div>
4 months agoCompliance - certificate under Reg. 74(5) of SEBI (DP) Regulations 2018
4 months agoClosure of Trading Window
5 months agoClosure of Trading Window
5 months agoUn audited Financial Results for the quarter ended 31.12.2025
6 months agoUn audited Financial Results for the quarter ended 31.12.2025
6 months agoResults for the quarter ended 31.12.2025
6 months agoResults for the quarter ended 31.12.2025
6 months agoThe Board Meeting to be held on 23/02/2026 has been revised to 13/02/2026 The Board Meeting to be held on 23/02/2026 has been revised to 13/02/2026
7 months agoVista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/02/2026 inter alia to consider and approve 1. Unaudited financial results for the quarter and nine months ended 31.12.2025.2. Limited Review Report quarter and nine months 31.12.2025.3. Any other business with the permission of the Chair.
7 months agoDisclosure
7 months agoCompliance - Certificate under Reg 74(5) of SEBI (DP) Regulations
7 months agoClosure of Trading Window
8 months agoUn audited financial Results for the quarter and half year ended 30.09.2025
9 months agoUn audited Financials Results for the quarter and half year ended 30.09.2025
9 months agoVista Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2025 inter alia to consider and approve 1. Unaudited financial results for the quarter ended 30.09.2025.2. Limited Review Report for quarter ended 30.09.2025.3. Any other business with the permission of the Chair.
10 months agoCompliance - certificate under Reg. 74(5) of SEBI (DP) Regulations 2018
10 months agoScrutinizers report and Outcome of AGM
11 months agoOutcome of AGM of Vista Pharmaceutical Limited held on 30.09.2025
11 months agoClosure of Trading Window under SEBI (Prohibition of Insider Trading Regulations) 2015
11 months agoIntimation - Newspaper publication of Notice of 34th Annual General Meeting of the company for Financial Year 2024-25
12 months agoIntimation of Book Closure regrading 34th Annual General Meeting of the company
12 months agoSubmission of Annual Report for the FY 2024-25
12 months agoNotice of 34th Annual General Meeting of Vista Pharmaceuticals Limited to be held on Tuesday 30th September 2025
12 months agoAnnual reports
Concalls & investor presentations
No presentations found
Corporate Actions
Date
Type
Details
No data available.
Company details
Registered office
Plot Nos. 10 To 14 And 16 To 20, T S I I C Industrial Estate Chityal, Gopalaipalli Village Narketpally Mandal Nalgonda Dist Telangana PIN: 508254 Tel No: 08682 272552 / 09291015956 Fax No: 08682 272551 Email: [email protected] Internet: www.vistapharmaceuticals.com
Registrars
1-2-285 , Domalaguda,,Hyderabad 1-2-285 Domalaguda NULL PIN: Tel No: 040-7642217/7634445 Fax No: 040-7632184 Email: NULL
Management
Dhananjaya Alli, Chairman
Murali Meraga, Managing Director
Pavan Sathvik Gilaka, Whole Time Director
Umesh V Banakar, Non Executive Independent Director
Divya Bhavani Chakravarthula, Non Executive Independent Director
Naga Raja Madineni, Non Executive Independent Director
Madhu Sudan Anchi, Non Executive Independent Director
Swapna Priya Gunduboina, Non Executive Independent Director
Anumala Ravi Chandra kumar, Non Executive Independent Director
Rama Mohan Manamasa, Non Executive Independent Director
Barkha Jain, Company Secretary & Compliance Officer
Stanley Prabhakar Reddy, Non Executive Director
Mallem Hanumantha Rao, Non Executive Director
Umakanth Katta, Non Executive Director
Divakar Reddy Yerrabommanahalli, Non Executive Director
Details
BSE 524711
NSE NULL
ISIN INE427C01021